This product is for research use only, not for human use. We do not sell to patients.
Size | Price |
---|---|
250mg | Get quote |
500mg | Get quote |
1g | Get quote |
Cat #: V20452 CAS #: 1257792-41-8 Purity ≥ 98%
Description: Hetrombopag (SHR8735; Herombopag; Hengqu) is a novel, potent, orally bioavailable, and non-peptide thrombopoietin (TPO) receptor agonist developed by Jiangsu Hengrui Pharmaceutical for the treatment of thrombocytopenia and aplastic anaemia. In June 2021, hetrombopag gained the first approval in China as a second-line treatment for primary immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA) in adults. Hetrombopag can be used to treat low platelet levels in people who have a certain blood disorder called chronic immune thrombocytopenia purpura or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Formula | C25H24N4O5 |
---|---|
CAS No. | 1257792-41-8 |
SMILES Code | O=C(C1=CC=C(C2=CC=CC(NNC3=C(C)NN(C4=CC=C5CCCCC5=C4)C3=O)=C2O)O1)O |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.